+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 70Years
All Genders
ID07897994

Comparing Linralase Glutarate Capsules Plus Amoxicillin with Bismuth Quadruple Therapy for First-Time Helicobacter pylori Infection Treatment

Led by Yongquan Shi · Updated on 2026-10-27

448

Participants Needed

24

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.

CONDITIONS

Brief Title

Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection

Research Team

Y

Yongquan Shi, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here